Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study for the effect on blood glucose fluctuation by switching from DPP-4 inhibitor to SGLT2 inhibitor or to DPP-4 inhibitor/SGLT2 inhibitor combination tablet in patients with type 2 diabetes. - multicenter, prospective, randomized, open-label, parallel group, comparison study -

Trial Profile

Study for the effect on blood glucose fluctuation by switching from DPP-4 inhibitor to SGLT2 inhibitor or to DPP-4 inhibitor/SGLT2 inhibitor combination tablet in patients with type 2 diabetes. - multicenter, prospective, randomized, open-label, parallel group, comparison study -

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canagliflozin (Primary) ; Canagliflozin/teneligliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms CALMER
  • Most Recent Events

    • 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
    • 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association.
    • 09 Apr 2019 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top